
Lupin completes acquisition of US-based Gavis Pharmaceuticals
pharmafile | March 10, 2016 | News story | Research and Development, Sales and Marketing | FDA, Gavis, Lupin, acquisition, generics
Indian drug manufacturer Lupin has announced the completion of its acquisition of New Jersey-based pharmaceutical firm, Gavis, in a deal worth $880 million.
As reported previously, the deal will see Lupin enhance its presence in the US generic market, with access to Gavis’ 62 generic drugs, which the firm has already filed to the FDA for approval.
72% of these ANDA filings pending approval requests represent niche dosage forms with 18 Para IVs and eight FTFs products. The existing pending approvals of Gavis address a market of over $9 billion.
Vinita Gupta, chief executive officer at Lupin, comments: “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as speciality pipeline.”
Sean Murray
Related Content

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Samsung Biologics has launched an all-cash public tender offer to acquire PolyPeptide Group in a …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment
EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …





